Skin Cancer Clinical Trial
Official title:
Spectral Diagnosis of Cutaneous Malignancy
The goal of this clinical research study is to evaluate the use of an imaging technology called spectral diagnosis. Researchers want to find out if a special spectral-diagnosis probe can be used to detect skin cancers.
The spectral-diagnosis probe being used in this study uses dim pulses of light to identify
features of tissue that may be related to the status of skin cancer. The probe is shaped like
a catheter, and it has a camera on the end, which takes pictures of the skin.
If you agree to take part in this study, you will be asked questions about your age, race,
smoking status, and the status of any diseases you may have (such as diabetes, connective
tissue disease, and infectious disease). It should take about 5 minutes to answer these
questions.
The study doctor will then decide which of your lesions are suitable for imaging by the
probe. If necessary, any hair on or around the lesion(s) will be shaved or trimmed. The
area(s) of skin being imaged will be cleaned with rubbing alcohol.
As part of your exam, the study doctor will use the probe to measure the selected areas of
tissue. To perform the spectral-diagnosis measurement, the probe will be gently placed on the
surface of your skin. Each selected area of your skin will take about a few seconds to image.
The probe will shine different types of light onto the skin, and it will collect the light
that reflects from the skin surface. The light signals will be stored so that researchers can
look at them. Preparing the lesion, imaging it, and collecting the light signals should take
about 10-15 minutes per lesion.
After all of the imaging is over, you will have biopsies performed on the lesions that your
study doctor has decided are in need of such treatment as part of your standard care.
After this clinic visit, your participation in the study will be over.
This is an investigational study. The imaging probe is not commercially available or FDA
approved. At this time, it is being used in research only. Up to 150 patients will take part
in this study. All will be enrolled at M. D. Anderson.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02721459 -
XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma
|
Phase 1 | |
Completed |
NCT03740815 -
Feasibility of Serratus Plane Block Associated With Sedation in Axillary Dissection
|
N/A | |
Recruiting |
NCT05779423 -
Cryoablation+Ipilimumab+Nivolumab in Melanoma
|
Phase 2 | |
Terminated |
NCT01468818 -
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
|
Phase 2 | |
Completed |
NCT01820234 -
Evaluation of Store-and-Forward Teledermatology Versus a Face-to-Face Assessment During a Skin Cancer Screening Event
|
N/A | |
Completed |
NCT00535769 -
Evaluation of Adherence to Topical Agents: Applying Communication Technology to Improve Sunscreen Use
|
Phase 0 | |
Completed |
NCT00526032 -
Melanoma Detection by Oblique-Incidence Optical Spectroscopy
|
N/A | |
Completed |
NCT00588341 -
Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection
|
Phase 2 | |
Active, not recruiting |
NCT01447199 -
The Molecular Predisposition to Hereditary Nonpolyposis Colon Cancer (HNPCC)
|
||
Enrolling by invitation |
NCT04758988 -
AI Augmented Training for Skin Specialists
|
N/A | |
Not yet recruiting |
NCT04534868 -
Patient Acceptance And Satisfaction of Teledermoscopy In General Practice In a Belgian Rural Area
|
N/A | |
Recruiting |
NCT04138342 -
Topical Fluorescent Nanoparticles Conjugated Somatostatin Analog for Suppression and Bioimaging Breast Cancer
|
Phase 1 | |
Completed |
NCT03673917 -
Cosmetology Students and Skin Cancer
|
N/A | |
Recruiting |
NCT04341064 -
Sun-safe Habits Intervention and Education
|
Phase 3 | |
Completed |
NCT04206995 -
Cancer Sensing: Evaluation of Odour Sampling Techniques
|
||
Recruiting |
NCT05574101 -
A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer
|
Phase 2 | |
Not yet recruiting |
NCT05860881 -
Topical Sirolimus in Chemoprevention of Facial Squamous Cell Carcinomas in Solid Organ Transplant Recipients (SiroSkin)
|
Phase 3 | |
Completed |
NCT05146622 -
Virtual Sun Safe Workplaces Ph I
|
||
Recruiting |
NCT05068310 -
Applicability of a Cellular Resolution Full-field OCT Image System for Pigmented and Non-pigmented Skin Tumors
|
||
Recruiting |
NCT03889899 -
Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia.
|
N/A |